Loading patent…
AssigneeUniversity of Southampton
InventorsMartin John Glennie, Aymen Al-Shamkhani, Mark Steven Cragg, Sean Hua Lim
Estimating the term…
The disclosure relates to a method of treatment or prevention of B-cell related disease in a subject comprising the administration of a binding molecule capable of binding to a B-cell and promoting killing of the B-cell; and an immunostimulatory agent arranged to stimulate effector lymphocytes, such as NK and/or T cells. Additionally, an anti-CD27 binding agent for use in a combination therapy with an anti-CD20 binding agent for the treatment or prevention of B-cell related disease in a subject. The disclosure also relates to a method of treatment or prevention of cancer in a subject comprising the administration of a cancer-cell-depleting binding agent capable of binding to the cancer cell and promoting killing of the cancer cell; and an immunostimulatory agent arranged to stimulate NK and/or T-cell activation. Additionally, an anti-CD27 binding agent for use in a combination therapy with a cancer-cell-depleting binding agent for the treatment or prevention of cancer in a subject.
A method of treatment or prevention of B-cell related disease in a subject comprising the administration of a binding molecule capable of binding to a B-cell and promoting killing of the B-cell;
The method according to any preceding claim, wherein the binding molecule capable of binding to a B-cell is an anti-CD20 binding molecule.
The method according to any preceding claim, wherein the B-cell binding molecule comprises an antibody, antibody fragment or antibody mimetic.
The method according to any preceding claim, wherein the B-cell binding molecule comprises:
The method according to any preceding claim, wherein the B-cell binding molecule is capable of ADCC or ADCP (Antibody-Dependent Cell-mediated Cytotoxicity/Phagocytosis) killing of the B-cell.
The method according to any preceding claim, wherein the B-cell binding molecule comprises a fully human monoclonal antibody of the IgG1 isotype.
The method according to any preceding claim, wherein the immunostimulatory agent arranged to stimulate NK cells, and optionally T cells, comprises or consists of a binding molecule arranged to bind to the NK and optionally T cells.
The method according to any preceding claim, wherein the NK- and optionally T-cell binding molecule comprises an anti-CD27 binding molecule.
The method according to any preceding claim, wherein the NK cell binding molecule is an agonist of the NK cell or NK cell activity;
The method according to any preceding claim, wherein the NK cell binding molecule comprises an antibody, antibody fragment or antibody mimetic.
The method according to any preceding claim, wherein the NK cell binding molecule comprises:
The method according to any preceding claim, wherein the NK- and optionally T-cell binding molecule is fully human monoclonal antibody of the IgG2 or IgG4 isotype.
The method according to any preceding claim, wherein the NK cell binding molecule does not bind or stimulate T-cells.
The method according to any preceding claim, wherein the administration of the B-cell binding molecule and the immunostimulatory agent is sequential.
The method according to any preceding claim, wherein the B-cell binding molecule and the immunostimulatory agent are administered between about 4 hours and about 48 hours apart.
The method according to any preceding claim, wherein the B-cell binding molecule and the immunostimulatory agent are administered between about 12 hours and about 24 hours apart.
The method according to any preceding claim, wherein the B-cell binding molecule and/or the immunostimulatory agent are administered in combination with another therapeutically active agent.
A method of treatment or prevention of B-cell related disease in a subject comprising the administration of an anti-CD20 binding molecule and an anti-CD27 binding molecule to the subject.
A method of treatment or prevention of B-cell related disease in a subject comprising the administration of rituximab and varlilumab to the subject.
An anti-CD27 binding agent for use in a combination therapy with an anti-CD20 binding agent for the treatment or prevention of B-cell related disease in a subject.
A composition comprising a B-cell binding molecule, such as an anti-CD20 binding agent and an immunostimulatory agent, such as an anti-CD27 binding agent.
A kit for treatment or prevention of B-cell related disease in a subject, the kit comprising a B-cell binding molecule, such as an anti-CD20 binding agent and an immunostimulatory agent, such as an anti-CD27 binding agent.
A method of treatment or prevention of cancer in a subject comprising the administration of a cancer-cell-depleting binding agent capable of binding to the cancer cell and promoting killing of the cancer cell;
An anti-CD27 binding agent for use in a combination therapy with a cancer-cell-depleting binding agent for the treatment or prevention of cancer in a subject.
A composition for treatment or prevention of cancer in a subject, the composition comprising a cancer-cell-depleting binding agent and an immunostimulatory agent, such as an anti-CD27 binding agent.
A kit for treatment or prevention of cancer in a subject, the kit comprising a cancer-cell-depleting binding agent and an immunostimulatory agent, such as an anti-CD27 binding agent.
Dependencies are inferred from the claim text.